Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019

IMPORTANCE: After US Food and Drug Administration (FDA) approval of a new drug, sponsors can submit additional clinical data to obtain supplemental approval for use for new indications. OBJECTIVE: To characterize pivotal trials supporting recent supplemental new indication approvals of drugs and bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhodapkar, Meera, Zhang, Audrey D., Puthumana, Jeremy, Downing, Nicholas S., Shah, Nilay D., Ross, Joseph S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193429/
https://www.ncbi.nlm.nih.gov/pubmed/34110392
http://dx.doi.org/10.1001/jamanetworkopen.2021.13224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193429/
https://www.ncbi.nlm.nih.gov/pubmed/34110392
http://dx.doi.org/10.1001/jamanetworkopen.2021.13224

Ejemplares similares